Skip to content
Black Week: 20% off everything, code BLACK

Search

What are you looking for?

Type at least 2 characters to see suggestions.

Livagen

Livagen

Livagen 20 mg is a synthetic short regulatory peptide from the family of tissue-specific bioregulators of the Khavinson school (Endogenic line), traditionally linked to the tetrapeptide Lys-Glu-Asp-Ala (KEDA) and assigned to the liver and hepatocyte – delivered as a lyophilisate in a vial for self-reconstitution. Research context: peptide bioregulation of liver cells, postulated influence on chromatin structure and hepatocyte regeneration in models. Research Use Only

59,99 €
With code BLACK: 47,99 € Lowest price in the 30 days before the discount: 59,99 €
Buy more, pay less
Fast shipping
Free delivery from 350 €
Returns policy
Peptide Calculator

Livagen 20 mg - liver bioregulator peptide

  • Livagen 20 mg is a synthetic short regulatory peptide from the family of tissue-specific bioregulators of the Khavinson school (Endogenic line), traditionally linked to the tetrapeptide Lys-Glu-Asp-Ala (KEDA) and assigned to the liver and hepatocyte - delivered as a lyophilisate in a vial for self-reconstitution.
  • Research context: peptide bioregulation of liver cells, postulated influence on chromatin structure and hepatocyte regeneration in models.

As a research reagent, Livagen has never been registered as a medicinal product in the EU, US or other jurisdiction. It should be clearly distinguished from Svetinorm — a peptide liver bioregulator from the Cytomax line (Russia), functioning in a separate regulatory framework. A Svetinorm is a separate regulatory entity in a specific jurisdiction; Livagen in the reagent market – in the lyophilisate vial format – is a Research Use Only material and is not a substitute for the medicinal product.

No EMA/FDA authorization as a medicine and no EFSA authorization as a dietary supplement ingredient. Livagen as a reagent it is not a hepatoprotector or an equivalent of silymarin — the communication of the product as a “liver peptide”, “liver protection for athletes”, “liver regenerator” or “detoxification support” is contrary to the Research Use Only framework.

Livagen is a synthetic short regulatory peptide derived from concept peptide bioregulation developed in St. Petersburg Institute of Bioregulation and Gerontology under the supervision of Vladimir Khavinson. In this research school, Livagen belongs to the family of tissue-specific regulatory peptides, traditionally associated with the tissue from which they were originally isolated or for which they are designed – in the case of Livagen this is liver and hepatocyte.

The conceptual assumption of the entire group is that short, several-amino acid peptides have affinity for a specific organ and modulate the function of its cells in a tissue-specific manner. The reagent belongs to the line Endogenous — materials mapping molecules of endogenous origin or directly derived from them, provided for research on peptide bioregulation of liver tissue.

This reagent is supplied by Livagen in a vials of 20 mg lyophilized powder for reconstitution. This format allows the researcher to independently select the volume of the solvent and set the working concentration according to the parameters of the planned experiment, and the lyophilisate ensures a longer shelf life of the material before dissolution than ready-made solutions. Purity verified by HPLC ≥98%, identity confirmed by mass spectrometry (Q-TOF), COA available for each batch.

General description - peptide bioregulation in the Khavinson school

The concept of peptide bioregulation is based on the observation that short peptides composed of two to four amino acid residues can influence cell function in a tissue-specific manner. In a series of works (Khavinson 2002; Anisimov, Khavinson 2010), Vladimir Khavinson and colleagues hypothesized that these types of peptides are part of an internal regulatory system that controls gene expression in response to the functional state and age of the tissue.

Within this concept, the entire family was distinguished research peptides assigned to specific organs: pineal gland, thymus, vessels, heart, cerebral cortex, bones – and the liver, for which the working name has become Livagen. Mechanistically, this school proposes that short regulatory peptides enter the cell and then interact with specific sites in the DNA strand or with proteins that regulate transcription, thereby modulating the expression of genes relevant to a given cell type.

For Livagen, the topic of the interaction of the peptide with the chromatin structure was particularly emphasized in the bioregulation literature: Khavinson and colleagues postulated that short peptides of this family can influence heterochromatin condensation and thus make previously “silenced” sections of the genome available for reading (Khavinson, Lezhava 2002 – Livagen and chromatin activation).

In tissue culture models, the influence of peptides of this family on the proliferation and differentiation of cells derived from the “mother” tissue of the peptide was observed (Chalisova et al. 2015 – tissue-specific peptide effects). The tissue specificity hypothesis is one of the most distinctive – and at the same time most controversial – elements of this concept, because it requires a mechanism for tissue recognition by a very short peptide sequence. More broadly, the Khavinson family of short regulatory peptides includes several recurring research themes:

  • Tissue-specific modulation of gene expression — hypothesis of the interaction of short peptides with DNA sequences and transcription factors
  • Effect on chromatin structure — postulated heterochromatin decondensation and gene activation, particularly exposed in the work on Livagen
  • Effect on cell proliferation and differentiation in tissue cultures derived from the “parent” organ of the peptide
  • Cytoprotective and antioxidant effects in cell models subjected to stress (oxidative, toxic)
  • Gerontological context — peptides as hypothetical modulators of processes related to tissue aging (Khavinson 2002; Anisimov, Khavinson 2010)

Livagen takes the place of a peptide in this family tissue-specific for the liver and hepatocyte — tools to study the concept of peptide bioregulation of the liver cell, its metabolic function, protection and regeneration in experimental models. The same organ-specific logic is reflected in related line bioregulators: Pancragen for the pancreas, Cardiogen for heart tissue, Bronchogen for the bronchopulmonary epithelium and Prostamax for the prostate.

In the same line of hepatic bioregulators, the bioregulation school literature also considers Svetinorm, a product with a separate regulatory status in the Cytomax line (Russia), which should not be confused with a research reagent (a distinction discussed below).

What is Livagen?

Chemically, Livagen is traditionally associated with a linear tetrapeptide sequence Lys-Glu-Asp-Ala (KEDA). In vial format it is supplied as a 20 mg lyophilized powder, requiring reconstitution before use.

  • Common name: Livagen, liver bioregulator peptide, liver peptide
  • Sequence (traditionally assigned): Lys-Glu-Asp-Ala (KEDA) — lysyl-glutamyl-asparaginyl-alanine; sequence for verification in the batch COA
  • Chemical class: synthetic short regulatory peptide (tetrapeptide); family of bioregulator peptides of the Khavinson school, tissue-specific lineage for the liver/hepatocyte
  • CAS number: for verification in the batch COA
  • Molar mass: dependent on confirmed sequence; for the KEDA variant of approximately 461 g/mol (indicative value – the mass from the MS analysis of the batch is binding)
  • Delivered form: white to off-white freeze-dried powder in vial, peptide content 20 mg; for reconstitution with bacteriostatic or sterile water before work; purity ≥98% HPLC
  • Conceptual origin: Khavinson’s concept of peptide bioregulation (St. Petersburg Institute of Bioregulation and Gerontology); Endogenic line; equivalent from the Cytomax line: Svetinorm (Russia) – a separate regulatory entity

Characteristics table

Parameter Value Attention
Sequence Lys-Glu-Asp-Ala (KEDA) traditionally assigned – for verification in the COA
CAS number for verification in the batch COA identity is decided by the party’s MS
Molar mass approx. 461 g/mol (KEDA variant) indicative value; the MS mass is binding
Class hepatic regulatory tetrapeptide Khavinson bioregulator family
Contents of the vial 20 mg of lyophilisate net peptide, declared in the COA
Character white/off-white freeze-dried powder for reconstitution before work
Cleanliness ≥98% HPLC UV detection, per batch verification
Equivalent (Cytomax line) Svetinorm (Russia) separate regulatory entity – not this reagent

Origin: Livagen originates from the tissue-specific peptide research program conducted at St. Petersburg Institute of Bioregulation and Gerontology. As part of this program, peptides were designed as short regulatory fragments assigned to specific organs, and then their effect on cells of a given tissue was examined in cultures and in animal models. Livagen was assigned to the liver and hepatocyte.

It should be emphasized that the exact sequence and chemical identity of peptides of this family in the reagent trade may be inconsistent – therefore the sequence and molar mass of each batch of Livagen require confirmation in a certificate of analysis (COA), and the KEDA sequence is given as traditionally assigned, not as an unconditionally established identity of each material on the market.

Mechanism of action at the molecular level

Livagen is considered in the literature through the prism of the concept of tissue-specific peptide bioregulation. The following description refers to hypotheses and observations from preclinical models – not to a validated human clinical mechanism. Profile observed and postulated in preclinical models:

  1. Tissue-specific peptide bioregulation of the hepatocyte — the central hypothesis of the Khavinson school assumes that short regulatory peptides enter the cell and modulate gene expression by interacting with specific DNA sequences or with the transcription apparatus. For Livagen, the postulated effect on chromatin decondensation — Khavinson and Lezhava described observations suggesting that the peptide may loosen heterochromatin condensation and thus make previously “silenced” genes in the cell available for reading (research context, unconfirmed clinical mechanism). Mechanism: postulated modulation of transcription and chromatin organization, not classic stimulation of the membrane receptor (Khavinson 2002; Khavinson, Lezhava 2002 – Livagen and chromatin activation)
  2. Modulation of the detoxification and metabolic function of the liver — in hepatocyte culture models and models of toxic load, the influence of peptides of this family on the parameters of the metabolic and detoxification function of the liver cell was examined; for Livagen, the research context is the modulation of hepatocyte activity under experimental conditions (Kuznik et al. 2020 – liver complex and KEDA tetrapeptide)
  3. Antioxidant and anti-inflammatory effects in liver tissue — the protective potential of the peptide against cellular damage was tested in models of liver tissue subjected to oxidative stress or toxic load; the research context includes protection of the hepatocyte against reactive oxygen species and modulation of inflammatory markers in liver tissue
  4. Support for hepatocyte regeneration in models — the influence of peptides of this family on the survival and renewal of liver cells was considered in tissue culture models and models of liver tissue damage; for Livagen, the research context is hepatocyte regeneration under experimental conditions

Characteristics of peptides of this family (based on the literature of the bioregulation school):

  • Short sequence (tetrapeptide) and low molecular weight – typical for the designed regulatory fragments
  • Postulated ability to penetrate the cell and affect the nuclear level, including the chromatin structure – a hypothesis requiring further mechanistic verification
  • The action is described as modulatory and contextual, rather than classically stimulating – the peptide is intended to “normalize” cell function, not to force a one-way response
  • Human pharmacokinetic profile: not characterized for the reagent; no data from randomized clinical trials

IMPORTANT DISTINCTION

The entire mechanism of tissue-specific peptide bioregulation – including the postulated effect of Livagen on chromatin decondensation and gene activation – remains a hypothesis developed mainly by the Russian scientific school (St. Petersburg Institute of Bioregulation and Gerontology) and is characterized by limited independent replication outside the home centers. Available data come from cellular and animal models – there are no large, randomized clinical trials confirming the described effects in humans.

The phrases “modulation of liver function”, “antioxidant effect” or “support of hepatocyte regeneration” in the context of this description refer only to observations in in vitro/in vivo models, and do not guarantee the effect in humans. In addition: Livagen as an RUO reagent is not a hepatoprotector or an equivalent of silymarin — a bioregulator peptide is a different category than a hepatoprotective drug, and the reagent is not its substitute. Pro-Body material is a Research Use Only reagent – not for use on humans or animals.

Important distinction - Russian school, Livagen vs Svetinorm, bioregulator vs hepatoprotector

Three distinctions are critical here and must not be merged into one.

First – data origin. The concept of tissue-specific peptide bioregulation is an original, consistently developed achievement Russian scientific school (St. Petersburg Institute of Bioregulation and Gerontology). It is characterized by limited independent replication outside its home centers and much of the literature in Russian. The data for Livagen comes from cell and animal models – not large randomized clinical trials.

This does not disqualify the concept, but sets a limit for interpretation: the observations are preliminary and require confirmation. This also applies to the most exposed topic – the effect of the peptide on chromatin condensation – which remains a mechanistic hypothesis.

Second – Livagen (RUO reagent) vs Svetinorm (Cytomax line). These are two separate regulatory entities. Svetinorm is a peptide liver bioregulator from the commercial Cytomax line (Russia), operating in a separate regulatory framework in its jurisdiction. Livagen in the reagent trade, it is a Research Use Only material – a chemical reagent for laboratory research, without registration as a drug in the EU, USA or other jurisdiction. Livagen RUO reagent is not a replacement Svetinorm product and does not replace medical consultation or medicinal product.

Third – bioregulator vs hepatoprotector. Livagen, as a bioregulator peptide, belongs to a different category than the classic hepatoprotective drug (e.g. preparations based on silymarin from milk thistle, ursodeoxycholic acid or phospholipids). Hepatoprotector is an agent with an established pharmacological mechanism and often authorized therapeutic status; Livagen is a short peptide studied in the framework of the tissue-specific bioregulation hypothesis, in preclinical models, as an RUO reagent. Livagen reagent it is not a substitute for hepatoprotector nor a “liver” drug – communication suggesting such equivalence is inconsistent with the Research Use Only framework.

Applications in scientific research

Livagen in the format of a lyophilized vial is used as a reagent in research work on the concept of peptide bioregulation of tissue-specific liver tissue, delivered in a form that allows you to independently determine the working concentration after reconstitution. In vitro models (hepatocyte cultures, liver tissue cultures, models of oxidative stress and toxic load) examine its impact on cell viability, regeneration, differentiation and markers of oxidative damage and inflammation.

In vivo models (animal models used by bioregulation centers) examined the influence of peptides of this family on tissue parameters related to liver function, tissue regeneration and aging. Specific research directions include:

  • The concept of peptide tissue bioregulation — Livagen as a model tissue-specific liver peptide; testing the hypothesis of modulation of gene expression by short peptides in hepatocytes
  • Peptide-chromatin interaction studies — Livagen as a model peptide in studies on the postulated heterochromatin decondensation and gene activation (Khavinson, Lezhava 2002 — Livagen and chromatin activation); characterization of the effect of a short peptide on the organization of nuclear DNA
  • Models of hepatoprotection in laboratory conditions — assessment of the protective potential against oxidative stress and toxic load in hepatocyte cultures
  • Regeneration and differentiation studies — the effect of the peptide on cell renewal parameters and hepatocyte differentiation markers in culture models
  • Experimental gerontology — bioregulatory peptides as tools for studying processes related to the aging of liver tissue (Anisimov, Khavinson 2010)
  • Independent and methodological verification — replication of observations of the bioregulation school in independent laboratories, including confirmation of the chemical identity and KEDA sequence of the tested material

Summary

Livagen 20 mg provides a synthetic short regulatory peptide (traditionally linked to the tetrapeptide Lys-Glu-Asp-Ala, KEDA) from the family of tissue-specific bioregulators of the Vladimir Khavinson school (St. Petersburg Institute of Bioregulation and Gerontology), Endogenic line – in the form of a lyophilized powder in a vial, for self-reconstitution. The peptide is attributed to the liver and hepatocyte, and the conceptual assumption is the modulation of liver cell gene expression by a short peptide, with the effect on chromatin structure particularly exposed in the school’s literature – the postulated decondensation of heterochromatin and gene activation.

The mechanism covers four main research threads: tissue-specific bioregulation of the hepatocyte, modulation of liver detoxification and metabolic function, antioxidant and anti-inflammatory effects in liver tissue, and support for hepatocyte regeneration – all in preclinical models. The whole concept remains mainly developed by the Russian school of science and is characterized by limited independent replication – data comes from cellular and animal models, without large randomized clinical trials.

Livagen research reagent must be distinguished from the product Svetinorm from the Cytomax line (Russia) and clearly indicate that Livagen is an RUO reagent it is not a hepatoprotector or an equivalent of silymarin. Regulatory Status – Research Use Only; WADA status: class S0 (non-approved substances), prohibited at all times. The sequence of each batch requires confirmation with the COA. The broader context of the Khavinson family of bioregulators and organ-related peptides includes, among others: cortical Cortagen and telomeric Epithalon 10mg; Some of the materials from this line are also available in the form of: peptides in capsules.

Bibliography

  1. Khavinson VKh (2002). Peptides and Aging. PubMed
  2. Khavinson VKh, Lezhava TA, Monaselidze JG, et al. (2002). Effects of Livagen peptide on chromatin activation in lymphocytes from old people. PubMed
  3. Kuznik BI, Khasanova NB, Ryzhak GA, et al. (2020). The influence of polypeptide liver complex and tetrapeptide KEDA on organism physiological functions in norm and age-related pathology. PubMed
  4. Anisimov VN, Khavinson VKh (2010). Peptide bioregulation of aging: results and prospects. PubMed
  5. Chalisova NI, Linkova NS, Zhekalov AN, et al. (2015). Peptide Regulation of Cells Renewal Processes in Kidney Tissue Cultures from Young and Old Animals. PubMed

Chemical reagent Research Use Only. Livagen 20 mg (Endogenic line) in the Pro-Body catalog is not a medicinal product, dietary supplement or food. It is not intended for administration to humans or animals outside a controlled experimental environment. Livagen is a short hepatic bioregulatory peptide of the Khavinson school, traditionally associated with the tetrapeptide Lys-Glu-Asp-Ala (KEDA) – sequence and mass confirmed by mass spectrometry in the batch COA conclusively determine the identity.

Livagen it is not registered as a medicine in the EU or the US, it is not a hepatoprotector or an equivalent of silymarin and does not replace medical consultation; it should be distinguished from Svetinorm (Cytomax line). The information in the description is of an educational and scientific nature and refers to observations reported in preclinical literature – it does not constitute medical advice or administration instructions.